GlassScriptPhysician profile
Aaron Shelub
NPI 1124103619
$5,992.97
in general payments reported to CMS, 2019-2025
14 companies · $909 in 2025
The $909 reported for 2025 was more than what 87% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $349 · 2020: $323 · 2021: $1,310 · 2022: $730 · 2023: $1,233 · 2024: $1,139 · 2025: $909.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,123 · Education: $159.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,122.72 |
| Education | $158.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shionogi INC | $1,374.45 | 2020-2025 | Fetroja |
| Gilead Sciences, INC. | $817.29 | 2019-2025 | Biktarvy |
| Insmed, INC. | $716.19 | 2019-2025 | Arikayce |
| Merck Sharp & Dohme LLC | $622.60 | 2019-2025 | Delstrigo, Pifeltro, Zerbaxa |
| Cipla USA INC. | $554.87 | 2021-2022 | |
| Paratek Pharmaceuticals, INC. | $534.82 | 2020-2025 | Nuzyra |
| Melinta Therapeutics, LLC | $406.14 | 2020-2025 | Rezzayo, Kimyrsa, Orbactiv |
| Abbvie INC. | $312.35 | 2021-2025 | Dalvance |
| Astellas Pharma US INC | $196.35 | 2023-2025 | Cresemba |
| Viiv Healthcare Company | $196.15 | 2022-2025 | Apretude |
| La Jolla Pharmaceutical Company | $132.02 | 2023-2024 | Xerava |
| Aimmune Therapeutics, INC. | $90.59 | 2025 | Vowst |
| Pfizer INC. | $22.46 | 2024 | |
| Octapharma USA, INC. | $16.69 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aaron Shelub listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.